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ABSTRACT
DNA ploidy and the proliferative potential in 88 brain tumours were investigated using the bromodeoxyuridine
labelling index (BrdUrd L1), S - phase fraction (SPF) and an argyrophilic nucleolar organizer regions (AgNOR)
technique. The study included 65 highly malignant (Alii - AIV), and 23 low-grade (AI - All) gliomas. One fragment
of the tumour was fixed in Carnoy's solution for AgNOR test, while the other fragments were used for flow
cytometric determination of the labelling index, SPF and DNA ploidy. For the BrdUrdLl, tumour samples from
each patient were incubated in vitro for one hour at 370 C with BrdUrd using a high pressure oxygen method. After
fixation and staining, the percentages of BrdUrd-labelied cells (BrdUrdLl) and unlabelled S-phase cells (SPF)
were evaluated. The tumours showed variability in the BrdUrdLi values, SPF and AgNOR counts/cell nucleus.
However, grade dependent differences in the proliferating rate were only found to exist on the basis of BrdUrdLi
and AgNOR counts. The same percentage of DNA aneuploidy (56 %) was found in high-grade as well as in low-
grade gliomas. A linear - regression analysis showed a significant correlation between the results of three applied
methods: BrdUrdLl, SPF and AgNOR counts.
INTRODUCTION
The results of radiotherapy in malignant brain
tumours are poor. Despite application of
different methods of treatment such as
surgery, brachytherapy, high LET radiotherapy,
radiosensitizers of hypoxic cells, hyperbaric
oxygen, or hypo and hyperfractionation, the
mean survival time after treatment is 1 to 2
years. Many radiobiological and biological
factors may influence the low radiosensitivity of
malignant gliomas to ionizing radiation. This
may be the reason of a significant capacity for
repair of sublethal damage and low inherent
radiosensitivity, as well as rapid growth rate,
great number of hypoxic cells, or poor
reoxygenation.
There is an increasing evidence that tumours
with a high proliferative rate could benefit from
an accelerated course of radiotherapy.
Therefore, the knowledge of the proliferative
potential is important in selecting proper
treatment for an individual patient and
predicting the prognosis. Also determination of
the tumour growth rate may be helpful in the
selection of patients with residual tumour after
surgery who may benefit from additional
chemotherapy or/(stereotactic) radiation therapy.
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The potential doubling time (Tpot) which is
the time required for a tumour population to
double its number in the absence of cell loss
[1] is considered to be the best method for
describing the dynamic cytokinetic parameters
of tumour cells. Although the method is useful
in the clinical practice for gliomas [2, 3], its
value in other tumours is still doubtful. The
method requires Lv. administration of iodo -
/bromodeoxyuridine (ldUrd/BrdUrd). Another
method, the BrdUrd labelling index (BrdUrdLl).
which shows greater usefulness in clinical
practice can be determined in vitro by
incubation of the thymidine analoque (BrdUrd)
with tissue fragments [4]. The growth rate of
tumours has also been measured by
estimating the S - phase fraction (SPF), or the
proliferative index (PI, I.e. the percentage of
cells in S + G2/M phases of the cell cycle)
using flow cytometry. Other methods include
monoclonal antibodies such as Ki-67 (MIB-1
monoclonal antibody), PCNA (proliferating cell
nuclear antigen) [5, 6, 7, 8], which specifically
stain cycling cells and argyrophilic nucleolar
organizer regions (AgNOR) technique [9]. The
silver staining technique selectively stains
some acidic proteins (AgNOR proteins)
assocciated with ribosomal genes, which
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reflect cell and nuclear activity [10]. It is a
simple, and cheap method which can be applied
to paraffin sections, making retrospective
studies possible. However, some concern still
exists as regards accuracy and reproducibility of
AgNOR quantifying methods.
The current study was undertaken with the aim
of comparing AgNOR counts in brain tumours
with two better established methods such as:
BrdUrd LI and SPF for investigating cell
proliferation. As the methods refer to the same
biological parameter the purpose of the study
was also to establish the degree of correlation
between these indices. The DNA ploidy of the
examined tumours was also analysed.
MATERIAL AND METHODS
Patients
There were 65 patients with highly malignant
(grade III - IV, 11), and 23 with low-grade
gliomas (I - II) (Table 1). The low-grade group
consisted of 13 men and 10 women, and in
grade III - IV there were 36 men and 28
women. Grade I - II gliomas included younger
patients (mean age 43.0 years), while in grade
III - IV group the mean age was 55.0 years.
Tab.1 Correlation between histology and grade of brain
tumours. Number of patients are shown in
brackets.
Kernohan
Histology
Grade
I Fibrillary astrocytoma (10)
Astrocytoma (4)
II Oligodendroglioma (2)
Mixed glioma (7)
Malignant astrocytoma (17)
III Malignant oligodendroglioma (11)
Mixed anaplastic astrocytoma (6)
IV Multiform glioblastoma (31)
Material
The specimens (about 0.5 cm3) from each
patient were delivered fresh from the operating
room shortly after excision. One or two
fragments of the tumour were fixed in Carnoy's
solution for AgNOR test, while other fragments
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were used for the determination of the BrdUrd
L1, SPF and DNA ploidy.
BrdUrd labelling index
In vitro incorporation of BrdUrd was carried
out according to the high pressure oxygen
method described by Steel and Bensted
(1965). The BrdUrd staining procedure and
flow cytometry have been described in detail
elsewhere [12]. Briefly, after 1 hour of
incubation with BrdUrd at 370 C, tumour
fragments were fixed in 70 % ethanol. They
were then minced into fragments and digested
into nuclei at 370 C with 0.4 mg/ml pepsin
(Sigma Chemicals, Poole, Dorset) in 0.1 M HCI
for 20 min. The nuclei suspension was filtered
through a 35 Ilm nylon mesh and centrifuged
at 2000 rpm for 5 min. The pellet was
resuspended in 2 M HCI for 12 min to
denaturate the DNA partially. After two washes
in phosphate-buffered saline (PBS), the pellet
was incubated in PBS containing 0.5 % normal
goat serum (NGS) (Sigma Chemicals), 0.5 %
Tween 20 (Sigma Chemicals) and a mouse-
derived anti-BrdUrd monoclonal antibody
(DAKO). After 1 hour, the nuclei suspension
was washed in PBS and suspended in
PBS/NGSlTween containing goat anti-mouse
IgG FITC conjugate (DAKO) for 1 hour. After
two further washes as in PBS, the suspension
was stained for total DNA with PBS containing
10 Ilg/ml propidium iodide (PI).
Flow-cytometric data analysis
The stained preparations were analysed with
a FACScan flow cytometer (Becton Dickinson
Immunocytometry Systems, Sunnyvale, CA,
USA). Doublets and clumps were excluded from
the analysis by gating on a bivariate distribution
of the red peak vs integral signal. Excitation of
the FITC-Iabelled cells and the DNA-associated
PI was accomplished with an argon-ion laser
tuned to 488 nm and operated at 15 mW. Ten
thousand events were collected in each
histogram. The BrdUrdLi was calculated as a
percentage of all BrdUrd-labelledcells in a
sample (without discrimination of diploid
subpopulation in aneuploid tumours). The S-
phase fraction was calculated with a FACScan
software programme, running on a Hewlett
Packard computer. The percentage of
aneuploidy was estimated·· by evaluating the
DNA index, i. e., the ratio of the modal DNA
fluorescence of abnormal to normal G1/0 cells.
Aneuploidy was assessed in cases in which the
normal and neoplastic cell populations gave two
separate peaks. Human lymphocytes were
used as a reference peak.
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Statistical analysis
The Student's t test was used to determine
the statistical significance of differences in the
BrdUrdLl, SPF and AgNORs counts (at p < 0.05
level). To test the relationship between tumour
grade and the results of the method applied, an
analysis of variance and Tukey HSD test for
unequal number of patients were applied. A
linear - regression analysis was performed to
determine the correlation between the three
applied methods (p < 0.05). Statistical
calculations were performed using a
STATISTICA ver 4.5 programme.
Tumour fragments were fixed in a Carnoy's
solution for 48h at40 C. Tissues were then
routinely processed and embedded in paraffin.
Sections (4Jlm thick) were dewaxed by
successive baths in xylene and ethanol, post-
fixed for 30 min in 3:1 (vol/vol) absolute
ethanol - acetic acid solution and then
rehydrated. AgNOR staining was carried out
using a solution of 1 volume of 2 % gelatine in
1 % aqueous formic acid and two volumes of
50 % silver nitrate. Silver staining was
performed at 370 C for 20 min. The silver
colloid was than washed off with distilled water,
the sections were dehydrated to xylene and
mounted. NORs were visualized as distinct
black intranuclear dots. The number of NORs
per cell nucleus from about 200 cells for each
slide were evaluated under the microscope
with a 100x oil immersion objective lens. When
large polycyclic structures (overlapping NOR)
were observed, they were counted as a single
AgNOR if individual AgNOR could not be
identified.
Ag-NOR staining technique
I
RESULTS
The brain tumours showed great variability in
the cell kinetic parameters based on: BrdUrd
L1, SPF and AgNOR counts. The BrdUrdLi
ranged from 0.3 to 9.9 %, SPF - from 1.0 -
44.4 %, and AgNOR counts/cell - from 0.25 -
5.18. For high-grade gliomas (III - IV) the
values for the three methods applied were the
highest (fig.1 a-c). The mean BrdUrdLi for
grade IV gliomas was significantly higher (2.9
%) than in grade I - II gliomas (1.0 %). The
highest mean number of AgNOR counts was
observed in grade IV gliomas 3.0/cell, however
the lowest mean value (1.6/cell) was found in
grade I - II gliomas. Only grade IV gliomas
showed a significantly higher number of
AgNORs/cell than grade II and other groups (I,
Fig. 1.
III IV
Kernohan grade
Box plots showing relationship between tumour
grade and a) BrdUrdLl, b) AgNOR count/cell
nucleus, e) SPF. Each symbol represents mean
value and standard error of the mean. Fig. 1 a.
Statistically significant relationship between
BrdUrdLi and tumour grade (p = 0.0017); (a) the
difference between tumour grade II and IV, p =
0.0305. Fig. 1 b. Statistically significant relationship
between AgNOR count/cell nucleus and tumour
grade (p. = 0.0000); (a) difference between tumour
grade I and IV, p = 0.0012; (b), difference between
tumour grade II and IV, p = 0.0002; (c) difference
between tumour grade III and IV, p = 0.0003. Fig. 1
c. The relationship between SPF and tumour grade.
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When cell kinetic parameters were calculated
for diploid and aneuploid tumours separately,
significantly higher values for aneuploid
tumours were observed only for BrdUrdLi and
SPF (Table 2). For diploid gliomas the
BrdUrdLi was only 1.68 %, while for aneuploid
tumours this value amounted to - 2.57 % (p =
0.0194). The same was true for the S - phase
haction, which in anueploid tumours was
significantly higher (15.45 %) than in diploid
tumours (6.06 %, P0.0000).
A linear - regression analysis showed a
significant correlation (p < 0.05) between the
BrdUrdLi and AgNOR counts (Fig. 2 a),
BrdUrdLi and SPF (Fig. 2 b), and SPF and
Agnor counts (Fig 2 c). DNA aneuploidy was
found in 56 % of high - grade and low-grade
gliomas. In low - grade gliomas 1 (7.6 %) of 13
aneuploid tumours was hyperdiploid (DNA
index = 1.4 - 1.8) and 10 (76.9 %) were
tetraploid (DNA index =1.9 - 2.0). Five (13.9 %)
of 36 high - grade aneuploid gliomas showed
hyperdiploid pattern of aneuploidy, 28 (78 %)
tetraploid, and 2 (5.5 %) hypertetraploid.
Tab. 2. Comparison of DNA ploidy with BrdUrdLi , SPF and AgNOR counts for brain tumours. * p = 0.0194, ** P = 0.0000.
BrdUrd LI (%) SPF (%)
Tumour
mean±SE mean±SE AgNOR count/cell nucleus
N mean±SE
diploid 39 1.68 ± 0.17 6.06± 0.60 2.06 ± 0.12
aneuploid 49 2.57 ± 0.30* 15.45 ± 1.63** 2.45 ± 0.15
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Fig. 2. A significant correlation (p < 0.05) between the BrdUrdLi and AgNOR count/cell nucleus (a). The BrdUrdLi and SPF (b)
and AgNOR count/cell nucleus and SPF (c).
78 Rep. Pract. Oncol. Radiother. 5 (3) 2000
Gash'lska et al.: DNA ploidy, bromodeoxyuridine labelling index..•
DISCUSSION
Differences in the proliferating rate between
and within groups of brain tumours were
determined on the basis of all three methods
under evaluation: BrdUrdLl, SPF and AgNOR
counts. The highest mean BrdUrdLl was
observed in glioblastoma (grade IV, 2.9 %) and
other high-grade gliomas (grade III, 2.3 %),
while it was lowest in low-grade (I - II) gliomas
(1.0 %). The present study showed LI values
similar to those found in other reports [2, 3, 13,
14]. The only discrepancy was found in
glioblastoma, for which some other authors
have quoted higher values than those obtained
by us. [15, 16]. This may be due to differences
in the in vivo and in vitro incorporation
procedure and to the use of
immunohistochemistry rather than flow
cytometry to detect the DNA precursor. The
difference might be due to discrimination by
the authors of diploid subpopulation in
aneuploid tumours in LI counting, or to the
different number of cases examined.
Several studies have been published on
BrdUrdLl in brain tumours, showing
significance of this parameter in patients'
survival [3, 13, 15, 17], and reccurence rate
[15, 18]. Some authors [3, 18] showed a
significantly greater probability of survival
among patients whose tumours had L1's less
than 1 - 3 %. This results might confirm our
data (19), which show that patients with a
higher proliferative potential - LI > 1.5 % have
significantly lower probability of survival, after
surgery, than those with a lower proliferative
potential (L1 < 1.5 %). Also a strong significant
correlation between low SPF < 3 % [20, 21],
low Ki-67 LI (6) and longer patients' survival
was shown. Thus the proliferative potential of
tumour cells may be more important than the
histopathological diagnosis, and should
therefore be considered as an important factor
in determining the prognosis of individual brain
tumour patients and of selecting treatment. If
more favourable outcome is due to slow
growth rather than to the sensitivity to adjuvant
therapies, patients with L1's of less than 1 %
should be treated primarily by surgical
resection. Treatment with radiation or
chemotherapy might be reserved until
malignant change or faster growth is observed.
Therefore, a proper method of determining the
tumour growth rate is necessary.
Silver staining for AgNORs is reported to be
helpful in assessing tumour proliferation and its
histological grade [9, 22], which is compatible
with our results. Also a correlation between the
number as AgNOR and survival has been
demonstrate [22, 23]. In our study, the number
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of AgNOR in grade IV ranged from 1.2 to 5.2,
and was within the same range as in other
author' calculations - from 1.8 to 5.8
[8, 9]. The lowest mean value (1.0) was
observed in grade I - II gliomas. The results
between low and high - grade groups were
statistically different. However, other authors
(8) have not found any correlation between the
degree of histologic differentiation or the
pathologic staging and the AgNOR counts.
The discrepancies between laboratories might
be caused by the use of different methods of
fixation of the material, different staining, or
different acuracy of the method for different
tumour types.
In our previous study on see of the cervix
[12], the number of AgNORs was found to be
in the same range as that in brain tumours. As
BrdUrdLl revealed much higher proliferative
rate for cervical tumour (range 2.7 - 30.4 %) in
comparison with brain tumours (range 0.3 - 9.9
%) this should show also higher AgNOR
counts. As this does not happen to be the
case, there may be AgNORs overlapping
(lower NORs dispersion) in cervical tumour,
which could point to the inacurracy of the
method and thus to the main drawback of the
method.
In our study, the number of SPF and the
AgNOR counts were correlated with BrdUrdLl,
which confirms some other authors' studies [5,
8, 24]. However, some authors have found no
correlation between BrdUrdLi and AgNOR
counts (25). It may perhaps be more difficult to
find a correlation for tumours with a relatively
low proliferative potential. As the
measurements of AgNOR counts give only an
indirect indication of cell proliferative activity,
and SPF is a stastic marker which does not
reflect active proliferation, BrdUrdLi seems to
be the most precise reflection of the
proliferation potential of tumour cells. The
BrdUrdLl shows the highest applicability in
clinical practice.
In our stUdy a relatively low rate of
aneuploidy was found in tumours. Fourty - nine
of 88 (56 %) tumours were aneuploid.
Surprisingly, the same percentage was
recorded for low - and high - grade gliomas.
Eveng lower incidence of aneuploidy (29.1 %)
in grade IV gliomas was observed by Danova
et al. (3). A higher incidence of aneuploidy
(57.3 - 89.0 %) in the high - grade was found
by other authors [5, 20]. In high - grade
gliomas tetraploid tumours were more common
than in low - grade tumours. Moreover, high -
grade gliomas were the only tumours to display
hypertetraploidy; this might be indicative of the
higher degree of malignancy of these tumours.
In our study, statistically significant higher
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proliferation rate was observed in the
aneuploid tumours, as assessed by the
BrdUrdLi and SPF, in comparison with diploid
tumours. This is in agreement with other
authors' findings for tumours of the same
localization [3, 18, 25].
Our data showed variability in the
proliferative rate, especially within the highly
malignant gliomas. However, the three
methods studied assessing the proliferative
rate; i.e. BrdUrdLl, SPF and AgNOR counts,
show correlation and seem to reflect accurate
proliferative activity of the tumour cells, and it
was only the SPF that was unable to reveal
grade dependent differences. There still exists
scarce and controversial information in the
literature on the prognostic value of the
AgNOR technique and SPF in gliomas. we
plan, therefore, to increase the number of
patients examined and compare experimental
results with the clinical outcome to test the
clinical prognostic value of the three methods
applied.
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